Background {#Sec1}
==========

Grade 2 glioma accounts for about 15--20% of all brain tumors in adults \[[@CR1]\]. According to the 2016 revision of the World Health Organization (WHO) classification of tumors of the central nervous system, the major pathological types of grade 2 low-grade gliomas (LGGs) include diffuse astrocytomas (wild-type *IDH1*, mutant *IDH1*, or not otherwise specified) and oligodendrogliomas (mutant *IDH1* and 1p/19q co-deletion or not otherwise specified) \[[@CR2]\]. The treatment modalities consist of surgery followed by observation, radiotherapy, chemotherapy, or chemoradiation \[[@CR3]\]. Although surgery can cure a proportion of patients, some patients still have recurrence after surgery, and the LGGs can even transform into high-grade gliomas. Basing on longer survival data compared with high-grade gliomas, postoperative treatment decisions about observation versus aggressive treatments must take into account possible clinical benefits and side effects which may affect quality of life. Nowadays, postoperative adjuvant treatment strategies depend on whether the patient has high-risk factors. However, high-risk factors have been changing in recent years. Formerly, six factors were considered to be high-risk (astrocytoma, age \> 40 years, Karnofsky performance score \[KPS\] \< 70, tumor dimension \> 6 cm, tumor crossing midline, preoperative neurological function deficits of moderate to severe degree). Since 2015, subtotal resection and age \> 40 years are regarded as main high-risk factors for LGGs \[[@CR4]\]. Compared with the low-risk population, patients with high-risk factors need aggressive treatments after surgery. European Organisation for Research and Treatment of Cancer (EORTC) 22845 is a prospective trial to compare early radiotherapy with deferred radiotherapy \[[@CR5]\]. A total of 314 patients with LGGs who had undergone surgical resection or biopsy were randomized to receive either early radiation therapy (RT) or delayed RT delivered when progression took place. The results showed that immediate postoperative radiotherapy improved progression-free survival (PFS) and provided better seizure control, but there was no impact on overall survival. Taken together, the results showed that patients with high-risk WHO grade 2 glioma can benefit from postoperative adjuvant RT. In addition, adjuvant RT alone and temozolomide (TMZ) alone were compared in EORTC 22033-26033 \[[@CR6]\]. No differences in PFS were observed between the two arms. Furthermore, the question remains: Can radiotherapy combined with chemotherapy improve clinical outcomes in high-risk patients with LGG? Radiation Therapy Oncology Group (RTOG) 9802, a prospective clinical trial, indicated improvement in both PFS and overall survival (OS) with six cycles of adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy following radiation, when compared with RT alone. In addition, the survival distribution continued to diverge over time \[[@CR7], [@CR8]\]. However, procarbazine is not available in China. In clinical practice, Chinese doctors often use radiotherapy combined with TMZ to treat these patients, although large-scale prospective studies are lacking. TMZ is an alkylating agent with the chemical property to cross the blood-brain barrier. One standard treatment for high-grade glioma is to take TMZ as concurrent and adjuvant chemotherapy \[[@CR9]--[@CR11]\]. However, in LGGs, further studies are indispensable to ascertain the role of TMZ in addition to RT. RTOG 0424, a single-arm phase II study, combined concurrent and adjuvant TMZ with RT to treat patients with LGG with at least three risk factors for relapse (age ≥ 40 years, preoperative tumor diameter ≥ 6 cm, astrocytoma histology, tumor crossing the midline, or a preoperative neurological deficit of more than mild extent) \[[@CR12]\]. The 3-year OS rate was 73.1%, which significantly exceeded not only historical controls but also hypothesis. Although RTOG 0424 unveiled that radiotherapy followed by TMZ chemotherapy for high-risk LGGs had survival benefits, it was a single-arm trial, and Chinese data is still lacking. As a result, we decided to carry out a randomized controlled trial (RCT) to confirm the advantage of TMZ chemotherapy added to RT for patients with high-risk LGGs.

Methods/design {#Sec2}
==============

Study objective {#Sec3}
---------------

The aim of this study is to compare the efficacy and safety of RT plus TMZ with RT alone for high-risk LGGs. Beyond that, we will focus on molecular features, in addition to histologic classification, to establish a more appropriate treatment modality for certain cohorts.

Study design {#Sec4}
------------

This is a multicenter, open-label, prospective RCT. The study has received ethical approval from the Chinese Ethics Committee of Registering Clinical Trials. The protocol is written in line with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines (see Additional file [1](#MOESM1){ref-type="media"}: SPIRIT checklist). Following informed consent, eligible patients will be allocated to an RT group (control group) or a chemoradiotherapy (CRT) group (experimental group). The flow diagram of the main procedures is illustrated in Fig. [1](#Fig1){ref-type="fig"}. Fig. 1Study flowchart. *RT* radiation therapy, *TMZ* temozolomide

Recruitment and informed consent {#Sec5}
--------------------------------

A total of 250 participants will be recruited from four centers in China (see Additional file [2](#MOESM2){ref-type="media"}). Registration can be done at any time after a patient is diagnosed as having a WHO grade 2 glioma. The enrollment period is expected to be completed within 5 years from the beginning of recruitment. Research staff are in charge of the screening process to make sure each participant matches the inclusion and exclusion criteria. An informed consent form (ICF) describing the detailed study procedures and illustrating the potential benefits and risks will be provided to all participants, so that they can decide whether or not to volunteer. A signed written ICF must be acquired from all patients or their legal representatives prior to their participation in this clinical trial.

Eligibility criteria {#Sec6}
--------------------

The inclusion criteria are as follows: Newly diagnosed supratentorial WHO grade 2 gliomaAged 18--39 years without total resection, or aged 40--70 years with any extent of resection or biopsyKPS ≥ 60No more than moderate neurological symptoms or signsThe interval between surgery and randomization is less than 12 weeksHave signed the ICF.

The exclusion criteria are as follows: WHO grade 1 glioma or high-grade glioma according to WHO's grading systemPatient has received prior RT to the head and neck regionPatient has received prior chemotherapySynchronous multiple primary malignant tumors excluding carcinoma of the cervix in situ or non-melanomatous skin cancerPatient's prior malignancy disease-free survival less than 5 yearsPatient has active infectionPatient is pregnant or breast-feeding.

Randomization {#Sec7}
-------------

Qualified patients will be randomized in a 1:1 ratio using the method of block randomization. The blocked randomization sequence is generated by the SPSS computer software, and the block size is determined by statisticians. After the patient has registered and signed the ICF, he or she will be allocated to the RT group or the CRT group by web-based central randomization. The allocation sequence is unavailable to the researchers who are enrolling participants or assigning interventions.

Interventions {#Sec8}
-------------

Eligible patients will be assigned 1:1 to the experimental (CRT) group or the control (RT) group. In the experimental group, patients will be treated with RT combined with adjuvant TMZ with or without concurrent TMZ. In the control group, patients will only have RT treatment. Both groups will receive the same intensity-modulated radiation therapy (IMRT). The radiation dose is 50--54 Gy given in 25--30 fractions (1.8--2.0 Gy once daily, 5 days per week). RT treatment volumes will be defined using preoperative and postoperative T2 or fluid-attenuated inversion recovery (FLAIR) on magnetic resonance imaging (MRI). Drug dose adjustments are allowed according to blood counts and adverse reactions. Concurrent chemotherapy is to receive oral TMZ, 75 mg/m^2^ per day, during RT. Concurrent TMZ can be used for 42 days continuously if the absolute neutrophil count (ANC) is not less than 1.5 × 10^9^ cells per L, the platelet count is not less than 100 × 10^9^ cells per L, and there is a non-hematological toxicity of grade 0 or 1 (except for alopecia, nausea, and vomiting) according to version 4.03 of the National Cancer Institute Common Toxicity Criteria (NCI-CTC). In the case of ANC less than 1.5 × 10^9^ cells per L but more than 0.5 × 10^9^ cells per L, platelet count less than 100 × 10^9^ cells per L but more than 10 × 10^9^ cells per L, or a non-hematological toxicity of grade 2, concurrent TMZ treatment should suspend until recovery to toxicity of grade 0 or 1. TMZ chemotherapy will be terminated when one of the following conditions occurs: ANC \< 0.5 × 10^9^ cells per L, platelet count \< 10 × 10^9^ cells per L, or non-hematological toxicity of grade 3 or 4.

Patients who are assigned to adopt adjuvant chemotherapy will be treated with six cycles of TMZ, 150--200 mg/m^2^ per day for 5 consecutive days, repeated every 4 weeks. There is a 28-day break during RT and adjuvant TMZ. The first cycle dose of adjuvant chemotherapy is 150 mg/m^2^. A higher dose of 200 mg/m^2^ is recommended in the subsequent cycles if ANC is not less than 1.5 × 10^9^/L, platelet count not less than 100 × 10^9^/L, and non-hematological toxicity of grade 0 or 1 (except for alopecia, nausea, and vomiting) during the first cycle. The dose will reduce by 50 mg/m^2^ if ANC is less than 1 × 10^9^ cells per L, platelet count is less than 50 × 10^9^ cells per L, or there is non-hematological toxicity of grade 3 during any period of adjuvant chemotherapy. Patients must discontinue adjuvant TMZ if grade 4 non-hematological is recorded, the dose of TMZ has reduced to less than 100 mg/m^2^, or grade 3 non-hematological reoccurs after dose reduction.

Outcomes {#Sec9}
--------

Our primary outcome is PFS, which is calculated from the date of randomization to the date of first reported disease progression or the date of death from any cause. Secondary outcomes are OS, adverse events, and cognitive function. OS is calculated from the date of randomization until death from any cause. Cognitive function will be assessed by the Mini-Mental State Examination (MMSE).

Adverse events (AEs) {#Sec10}
--------------------

Investigators should explain to participants in detail that they are required to faithfully reflect changes in their condition during and after treatment. Researchers should pay close attention to AEs while observing the curative effect. The following information should be recorded in the case report form (CRF): symptom, occurrence time, severity, duration, treatment measures, and outcomes. Researchers should evaluate the association between AE and treatment and record them timely and truly with signature and date. The grading of AEs will be in accordance with CTC-AE version 4.03.

Baseline and follow-up visits {#Sec11}
-----------------------------

After obtaining written informed consent, a baseline assessment including a physical examination, KPS, complete blood count (CBC), and serum biochemistry will be completed within 7 days before interventions. Postoperative head MRI and cognitive function test are allowed to complete within 28 days prior to treatment. During treatment, CBC and serum biochemistry (including renal and liver function, electrolytes, and lactate dehydrogenase) will be conducted weekly. The first follow-up visit (KPS, head MRI, cognitive function) will be 1 month after radiotherapy. These visits will then occur every 3 months during the first 2 years, every half year from 3 to 5 years, and at least annually thereafter. Participants will be followed up for 10 years after the end of treatment for the last patient. The schedule of assessments before, during, and after treatment is displayed in Table [1](#Tab1){ref-type="table"}. Table 1Study schedule of enrollment, interventions, and assessmentsStudy periodEnrollmentAllocationPost allocationTime point−4 weeks0Week 0--6Week 10Weeks 11--34Within 2 years3--5 years5--10 yearsEnrollment: Eligibility screenX Informed consentX RandomizationX AllocationXInterventions: RTX Concurrent TMZX Adjuvant TMZXXAssessments: Physical examinationXEvery 3 monthsEvery 6 monthsAnnually KPSXXEvery 3 monthsEvery 6 monthsAnnually CBCXWeeklyXWeekly Serum biochemistryXWeeklyXWeekly Postoperative head MRIXXEvery 3 monthsEvery 6 monthsAnnually Cognitive functionXXEvery 3 monthsEvery 6 monthsAnnually Adverse eventsXXXEvery 3 monthsEvery 6 monthsAnnually*Abbreviations*: *RT* radiation therapy, *TMZ* temozolomide, *KPS* Karnofsky performance score, *CBC* complete blood count, *MRI* magnetic resonance imaging

Sample size {#Sec12}
-----------

This RCT is designed as a superiority trial. Based on literature reports and clinical experience, the median OS of the RT group is 7.8 years and that of the CRT group (RT plus TMZ) is 13.3 years. One-sided log-rank testing with a significance level of 0.05, a test power of 80%, and a withdrawal and loss of follow-up rate of 10% is applied in this trial. A 10-year follow-up for patient events will be conducted after the end of treatment for the last patient. The sample size estimated by PASS 11 software is 125 subjects per group.

Data collection and management {#Sec13}
------------------------------

All relevant information for each subject should be recorded in the CRF and inputted in ResMan, an Internet-based electronic data capture system, timely and truly by trained research staff. The personal information of each subject is confidential. In order to promote participant retention, researchers will instruct subjects to take their medication as prescribed. Patients will also be informed of the follow-up visits by telephone in advance, and all items will be measured in strict accordance with the assessments schedule shown in Table [1](#Tab1){ref-type="table"}. Two data entry staff are needed to input the data independently. After reviewing and confirming that the database is correct, electronic data will be conserved and backed up. As original material, the CRF is not easily changed. The researcher has to sign and date the CRF when it is necessary to modify. The locked electronic data files do not allow any changes to be made. The database will be statistically analyzed by statistical analysts as required by the statistical plan. The principal investigator has access to the final dataset, while other investigators are prohibited from entering. Except for the name-related data, the disclosure of the information to third parties is prohibited. After the completion of the trial, the responsible unit of the study has the right to publish contents related to the experiment in the form of a paper.

Data analysis {#Sec14}
-------------

Professional statisticians undertake statistical analysis tasks and participate in the whole process from trial design and implementation to analysis and summary. The Kaplan-Meier method will be used to estimate median PFS and OS, and a log-rank test will be used to compare differences between the two arms. Furthermore, a Cox proportional hazards analysis will be done to estimate the hazard ratio (HR) and 95% confidence interval (CI). Regarding prognostic factors, univariate and multivariate analyses including age, histology, treatment method, *IDH* mutation, 1p/19q status, and *MGMT* promoter status will be used to analyze their impact on PFS and OS. Safety analysis, mainly for AEs, will be done in the safety set (SS) population. All effectiveness analysis (PFS, OS, cognitive function) will be done on an intention-to-treat (ITT) set. The ITT analysis will be put to use to handle non-compliance and missing data.

Data monitoring {#Sec15}
---------------

To ensure the safety and validity of the trial, the data will be overseen by an independent Data Safety Monitoring Board (DSMB) during the study period. The board consists of clinicians and statisticians and will monitor all implementation activities including but not limited to the enrollment of each center, starting time of procedures, and drop out. All AEs and issues concerning interventions will be reported to the DSMB in line with requirements. All data entered into the database will be checked by the DSMB before being locked, and no changes will be permitted. To ensure data security, data must be backed up in time, and irrelevant personnel cannot access and modify data.

Discussion {#Sec16}
==========

Optimal adjuvant management of adult low-grade gliomas (LGGs) is controversial. RTOG 9802 has shown striking survival improvements for patients with LGGs treated with adjuvant RT followed by PCV chemotherapy, and there is a significant average MMSE score increase in both arms \[[@CR13]\]. But obviously, the incidence of AEs in the CRT group is higher than in the RT group. Thus, it is crucial to weigh the efficacy and safety of these treatments and further clarify how to combine them. Pathological molecular typing is an essential component of diagnosis and treatment of glioma at present. This clinical trial is the first large-scale prospective study to compare the effect of RT alone with RT plus TMZ involving molecular subtypes in high-risk patients with LGGs. The outcomes of this trial are expected to evaluate the predictive effects of diverse molecular markers (*IDH1*/*IDH2* mutations, 1p/19q co-deletion, *MGMT* promoter methylation status) and to find corresponding appropriate treatment patterns.

Cognitive function has aroused extensive concern in patients with brain tumors. EORTC 22033-26033, a prospective study of patients with LGGs, revealed no significant difference between the RT group and the TMZ group \[[@CR14]\]. Therefore, it did not back the treatment of TMZ alone over RT alone. In our study, the MMSE, a widely used screening test for dementia and cognitive dysfunction and a practical approach for ranking the cognitive state \[[@CR15]--[@CR18]\], will be applied to assess cognitive function in both randomly assigned arms. It may affect the choice of individual therapeutic strategy for patients with LGGs if RT plus concomitant and adjuvant TMZ improves survival outcomes without additional cognitive function damage compared to RT alone.

Trial status {#Sec17}
------------

The final protocol version is 1.0, dated 11 February 2018. Patient recruitment began on 10 April 2018 after we acquired ethical approval, and it is ongoing. We anticipate the recruitment phase to be complete by April 2023.
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**Additional file 1.** SPIRIT 2013 checklist: recommended items to address in a clinical trial protocol and related documents. **Additional file 2 Research centers.**

AE

:   Adverse event

ANC

:   Absolute neutrophil count

CBC

:   Complete blood count

CI

:   Confidence interval

CRF

:   Case report form

CRT

:   Chemoradiotherapy

DSMB

:   Data Safety Monitoring Board

FLAIR

:   Fluid-attenuated inversion recovery

HR

:   Hazard ratio

ICF

:   Informed consent form

IDH

:   Isocitrate dehydrogenase

IMRT

:   Intensity-modulated radiation therapy

ITT

:   Intention-to-treat

KPS

:   Karnofsky performance score

LGG

:   Low-grade glioma

MMSE

:   Mini-Mental State Examination

MT

:   Mutant

NCI-CTC

:   National Cancer Institute Common Toxicity Criteria

OS

:   Overall survival

PCV

:   Procarbazine, lomustine, and vincristine

PFS

:   Progression-free survival

RCT

:   Randomized controlled trial

RT

:   Radiation therapy, radiotherapy

SPIRIT

:   Standard Protocol Items: Recommendations for Interventional Trials

SS

:   Safety set

TMZ

:   Temozolomide

WT

:   Wild-type
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